Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine for Insulin Sensitivity in T2DM
NCT06203275Phase 3Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of paroxetine in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Change in glycated Hemoglobin at 3 months and Change in HOMA-IR at 3 months. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
paroxetine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06203275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203275.